| pubmed-article:11335792 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11335792 | lifeskim:mentions | umls-concept:C0226896 | lld:lifeskim |
| pubmed-article:11335792 | lifeskim:mentions | umls-concept:C0205531 | lld:lifeskim |
| pubmed-article:11335792 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:11335792 | lifeskim:mentions | umls-concept:C1527415 | lld:lifeskim |
| pubmed-article:11335792 | lifeskim:mentions | umls-concept:C0010592 | lld:lifeskim |
| pubmed-article:11335792 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:11335792 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:11335792 | lifeskim:mentions | umls-concept:C0332157 | lld:lifeskim |
| pubmed-article:11335792 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:11335792 | lifeskim:mentions | umls-concept:C1521801 | lld:lifeskim |
| pubmed-article:11335792 | lifeskim:mentions | umls-concept:C0205373 | lld:lifeskim |
| pubmed-article:11335792 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:11335792 | pubmed:dateCreated | 2001-5-3 | lld:pubmed |
| pubmed-article:11335792 | pubmed:abstractText | The objective of this study was to define the minimally effective dose of cyclosporin A (CsA) that would result in a maximal increase of the systemic exposure to oral paclitaxel. Six evaluable patients participated in this randomized cross-over study in which they received at two occasions two doses of 90 mg/m(2) oral paclitaxel 7 h apart in combination with 10 or 5 mg/kg CsA. Dose reduction of CsA from 10 to 5 mg/kg resulted in a statistically significant decrease in the area under the plasma concentration-time curve (AUC) and time above the threshold concentrations of 0.1 microM (T>0.1 microM) of oral paclitaxel. The mean (+/-SD) AUC and T>0.1 microM values of oral paclitaxel with CsA 10 mg/kg were 4.29+/-0.88 microM x h and 12.0+/-2.1 h, respectively. With CsA 5 mg/kg these values were 2.75+/-0.63 microM x h and 7.0+/-2.1 h, respectively (p=0.028 for both parameters). In conclusion, dose reduction of CsA from 10 to 5 mg/kg resulted in a significant decrease in the AUC and T>0.1 microM values of oral paclitaxel. Because CsA 10 mg/kg resulted in similar paclitaxel AUC and T>0.1 microM values compared to CsA 15 mg/kg (data which we have published previously), the minimally effective dose of CsA is determined at 10 mg/kg. | lld:pubmed |
| pubmed-article:11335792 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11335792 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11335792 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11335792 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11335792 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11335792 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11335792 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:11335792 | pubmed:issn | 0959-4973 | lld:pubmed |
| pubmed-article:11335792 | pubmed:author | pubmed-author:BeijnenJ HJH | lld:pubmed |
| pubmed-article:11335792 | pubmed:author | pubmed-author:RosingHH | lld:pubmed |
| pubmed-article:11335792 | pubmed:author | pubmed-author:van... | lld:pubmed |
| pubmed-article:11335792 | pubmed:author | pubmed-author:ten Bokkel... | lld:pubmed |
| pubmed-article:11335792 | pubmed:author | pubmed-author:SchellensJ... | lld:pubmed |
| pubmed-article:11335792 | pubmed:author | pubmed-author:SwartMM | lld:pubmed |
| pubmed-article:11335792 | pubmed:author | pubmed-author:KoopmanF JFJ | lld:pubmed |
| pubmed-article:11335792 | pubmed:author | pubmed-author:DuchinKK | lld:pubmed |
| pubmed-article:11335792 | pubmed:author | pubmed-author:LieverstJJ | lld:pubmed |
| pubmed-article:11335792 | pubmed:author | pubmed-author:MalingréM MMM | lld:pubmed |
| pubmed-article:11335792 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11335792 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:11335792 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11335792 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11335792 | pubmed:pagination | 351-8 | lld:pubmed |
| pubmed-article:11335792 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:meshHeading | pubmed-meshheading:11335792... | lld:pubmed |
| pubmed-article:11335792 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11335792 | pubmed:articleTitle | The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. | lld:pubmed |
| pubmed-article:11335792 | pubmed:affiliation | Department of Medical Oncology, Netherlands Cancer Institute/Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands. apmmg@slz.nl | lld:pubmed |
| pubmed-article:11335792 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11335792 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11335792 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:11335792 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11335792 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11335792 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11335792 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11335792 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11335792 | lld:pubmed |
